Lincoln Pharmaceuticals
645.80
-27.50(-4.08%)
Market Cap₹1,293.52 Cr
PE Ratio15.36
IndustryHealthcare
Company Performance:
1D-4.08%
1M+10.58%
6M+21.19%
1Y+10.84%
5Y+136.43%
View Company Insightsright
More news about Lincoln Pharmaceuticals
07Aug 25
Lincoln Pharma Reports 17% Net Profit Growth in Q1, Targets ₹1,000 Crore Revenue in 3 Years
Lincoln Pharmaceuticals reported strong Q1 FY26 results with a 17% increase in net profit to ₹27.70 crore and a 7.3% rise in total income to ₹169.34 crore. EBITDA grew by 17.92% to ₹39.08 crore. The company aims to achieve ₹1,000 crore in revenue within three years, targeting 15-18% annual growth. Lincoln Pharma launched a bulk drug manufacturing plant and received approvals for 10 products. The company's shares closed at ₹576.90 on BSE, up 8.47%.
 no imag found
07Aug 25
Lincoln Pharmaceuticals Reports 16.93% Profit Growth in Q1, Reappoints Key Directors
Lincoln Pharmaceuticals reported a 16.93% year-on-year increase in Q1 net profit to Rs. 27.70 crore. Total income rose by 7.39% to Rs. 169.34 crore, while EBITDA grew 17.92% to Rs. 39.08 crore. The company re-appointed key leadership positions, including Mahendra G. Patel as Managing Director. Lincoln aims to achieve Rs. 1,000 crore revenue within three years, targeting 15-18% annual growth. The company plans to expand its global presence from 60+ to 90 countries in 2-3 years. FII stake in the company increased from 3.95% to 5.13% over the past year.
 no imag found
02Jul 25
Lincoln Pharmaceuticals Completes Trial Run at Khatraj Facility, Eyes API Production
Lincoln Pharmaceuticals has successfully completed the trial run of its Khatraj facility, a key step in its expansion plans. The company aims to commence commercial production of Active Pharmaceutical Ingredients (APIs) at this facility within 1-2 years, subject to regulatory approvals. This move is expected to enhance manufacturing capabilities, potentially leading to vertical integration, cost efficiency, improved quality control, and stronger market positioning.
 no imag found
Lincoln Pharmaceuticals
645.80
-27.50
(-4.08%)
1 Year Returns:+10.84%
Industry Peers
Sun Pharmaceutical
1,808.30
(+1.66%)
Divis Laboratories
6,502.50
(-0.48%)
Torrent Pharmaceuticals
4,185.10
(-1.10%)
Dr Reddys Laboratories
1,322.90
(-0.52%)
Cipla
1,309.60
(-0.61%)
Lupin
2,305.20
(-0.27%)
Mankind Pharma
2,246.70
(-0.45%)
Zydus Life Science
891.90
(-2.08%)
Aurobindo Pharma
1,389.50
(-0.52%)
Glenmark Pharmaceuticals
2,406.30
(-0.31%)